



**PRODUCT: Dupixent® (dupilumab)**

**COMPANY:** Regeneron Pharmaceuticals, Inc. and Sanofi

**THERAPEUTIC AREA & INDICATION:**

Single dose pre-filled pen technology to treat adults and adolescents with atopic dermatitis (eczema), asthma and rhinosinusitis with nasal polyposis

---

**ABOUT THE PRODUCT**

Type 2 inflammation is an overactive immune response that plays a major role in diseases like atopic dermatitis, asthma and chronic rhinosinusitis with nasal polyposis. For decades, scientists have evaluated ways to inhibit the biologic pathways that underlie these types of diseases. Dupixent® (dupilumab) is the first fully human monoclonal antibody that inhibits the signaling of interleukin-4 (IL-4) and interleukin-13 (IL-13), two proteins that are key and central drivers of type 2 inflammation. Regeneron and Sanofi are also studying dupilumab in a broad range of clinical development programs for diseases driven by type 2 inflammation or other allergic processes.